Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24016025 | 1.00 | L3MBTL1 (0.47) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| SCHEMBL18737228 | 0.95 | L3MBTL1 (0.50) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| SCHEMBL28166486 | 0.93 | L3MBTL1 (0.49) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2207480 | 0.93 | L3MBTL1 (0.49) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| SCHEMBL21005661 | 0.93 | L3MBTL1 (0.49) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| SCHEMBL18638771 | 0.93 | L3MBTL1 (0.49) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| Fluoride SCHEMBL29252822 | 0.92 | L3MBTL1 (0.47) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| Bromide SCHEMBL23004553 | 0.92 | L3MBTL1 (0.47) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29252417 | 0.92 | L3MBTL1 (0.47) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2209793 | 0.92 | L3MBTL1 (0.47) | L3MBTL1TDP1CFTRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023206665-A1 | PROCESS FOR UNPROTECTED ASYMMETRIC PREPARATION OF NICOTINE | 凯特立斯（深圳）科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230144322-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECHNOLOGY, LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023062109-A1 | ORAL FORMULATIONS COMPRISING NICOTINE SALT | WM19 HOLDING AG (CH) | 2023-04-20 | — | — | WO | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| WO-2023279105-A1 | AZETIDINYL PYRIMIDINES AND USES THEREOF | AERIE PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10294243-B2 | Bicyclic compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| CN-106744853-B | A kind of graphene/black phosphorus nanometer sheet/nitrogen containing plasma liquid composite aerogel and preparation method thereof | 深圳大学 | 2019-04-26 | — | — | CN | disclosed |
| CN-106744854-B | A kind of graphene/black phosphorus quantum dot/nitrogen containing plasma liquid composite aerogel and preparation method thereof | 深圳大学 | 2019-04-26 | — | — | CN | disclosed |
| US-9974790-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180064829-A1 | FLUORESCENT BISPHOSPHONATE ANALOGS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-03-08 | — | — | US | disclosed |
| US-9832999-B1 | Bicyclic compounds as pest control agents | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170101422-A1 | Bicyclic compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2017-03-16 | — | — | US | disclosed |
| US-8623893-B2 | Pyridino-pyridinone derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | L3MBTL1 2309/4885TDP1 1172/4885CFTR 4604/4885 |
| US-20230144322-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | FOLH1, PSMA2, PSMA6 | L3MBTL1 3997/4885TDP1 3034/4885CFTR 3918/4885 |
| US-20180064829-A1 | FLUORESCENT BISPHOSPHONATE ANALOGS | PPIP5K2, PHPT1, PTH1R | L3MBTL1 3438/4885TDP1 4755/4885CFTR 3015/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | L3MBTL1 4512/4885TDP1 3195/4885CFTR 2599/4885 |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885TDP1 1532/4885CFTR 43/4885 |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | L3MBTL1 2309/4885TDP1 1172/4885CFTR 4604/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | L3MBTL1 2309/4885TDP1 1172/4885CFTR 4604/4885 |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885TDP1 1532/4885CFTR 43/4885 |
| US-10294243-B2 | Bicyclic compounds as pesticides | DDT, BCHE, CYCS | L3MBTL1 340/4885TDP1 2969/4885CFTR 3409/4885 |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ERBB2, ERBB3, BRCA1 | L3MBTL1 1283/4885TDP1 2864/4885CFTR 1685/4885 |
| US-20170101422-A1 | Bicyclic compounds as pesticides | DDT, BCHE, CYCS | L3MBTL1 340/4885TDP1 2969/4885CFTR 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.